High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Clinical Oncology

• Publication date

  2001-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2001.19.9.2370PMID 11331315
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.

  2001cited by this paper
• A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: differential immunogenicity of Melan-A27-35 and Melan-A26-35.

  2000cited by this paper
• Melan-A/MART-151–73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells

  2000cited by this paper
• Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma

  2000cited by this paper
• A new American Joint Committee on Cancer staging system for cutaneous melanoma

  2000cited by this paper
• NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.

  2000cited by this paper
• Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.

  2000cited by this paper
• Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.

  2000cited by this paper
• High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

  2000cited by this paper
• Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.

  2000cited by this paper
• A direct comparison of cytolytic T‐lymphocyte responses to Melan‐A peptides in vitro: differential immunogenicity of Melan‐A27‐35 and Melan‐A26‐35

  2000cited by this paper
• Adjuvant therapy of melanoma with interferon‐alpha‐2b is associated with mania and bipolar syndromes

  2000cited by this paper
• In Vitro Priming with Adenovirus/gp100 Antigen-Transduced Dendritic Cells Reveals the Epitope Specificity of HLA-A*0201-Restricted CD8+ T Cells in Patients with Melanoma1

  2000cited by this paper
• A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy.

  1999cited by this paper
• Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in‐transit melanoma metastases

  1999cited by this paper
• Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b.

  1998cited by this paper
• Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): Correlation with survival

  1998cited by this paper
• Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial.

  1998cited by this paper
• Neurotoxicity of interferon‐α in melanoma therapy

  1998cited by this paper
• Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene.

  1998cited by this paper
• Ganglioside vaccines with emphasis on GM2.

  1998cited by this paper
• Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b.

  1998cited by this paper
• Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma.

  1998cited by this paper
• Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine.

  1998cited by this paper
• Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.

  1998cited by this paper
• Effect of IFN-α on Tumor-Infiltrating Mononuclear Cells and Regressive Changes in Metastatic Malignant Melanoma

  1998cited by this paper
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  1998cited by this paper
• The Large Sample Distribution of the Weighted Log Rank Statistic Under General Local Alternatives

  1997cited by this paper
• Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system.

  1997cited by this paper
• Phase III trial of melacine?? melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma: 179

  1997cited by this paper
• Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

  1996cited by this paper
• Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment.

  1996cited by this paper
• The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100.

  1996cited by this paper
• GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.

  1995cited by this paper
• Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.

  1994cited by this paper
• Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma.

  1993cited by this paper
• Ganglioside expression on human malignant melanoma assessed by quantitative immune thin‐layer chromatography

  1993cited by this paper
• [The adjuvant therapy of malignant melanoma].

  1992cited by this paper
• Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.

  1989cited by this paper
• Adjuvant therapy for malignant melanoma.

  1981cited by this paper
• Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial.

  1981cited by this paper

• Precision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade.

  2026cites this paper
• Advances in melanoma immunotherapy: harnessing vaccination as a potential novel immunotherapeutic strategy.

  2026cites this paper
• mRNA and Peptide Vaccines in Melanoma-Current Landscape and Future Direction.

  2026cites this paper
• Synergistic interactions and optimal sequencing of chemotherapy and immunotherapy in cancer treatment

  2026cites this paper
• A Case Report of Primary Malignant Melanoma of the Cervix

  2026cites this paper
• Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development

  2025cites this paper
• Interferon-Based Therapeutics in Cancer Therapy: Past, Present, and Future

  2025cites this paper
• Malignant Melanoma of the Tongue: A Scoping Review

  2025cites this paper
• Application and Research Progress of Zidovudine and Interferon-α Combination Therapy

  2025cites this paper
• Extracellular matrix rigidity controls breast cancer metastasis via TYK2-mediated mechanotransduction

  2025cites this paper
• Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients

  2025cites this paper
• Design considerations for randomized comparisons of neoadjuvant–adjuvant versus adjuvant-only cancer immunotherapy when tumor measurement schedules do not align (SWOG S1801)

  2025cites this paper
• Efficacy and safety of cancer vaccine therapy in malignant melanoma: a systematic review

  2025influential citation
• IFNλ1 is a STING-dependent mediator of DNA damage and induces immune activation in lung cancer

  2025cites this paper
• Evolving Trends in Breast Cancer Immunotherapy: Recent Updates

  2025cites this paper
• Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.

  2024cites this paper
• Eliciting prior information from clinical trials via calibrated Bayes factor

  2024cites this paper
• Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches.

  2024cites this paper
• Cytokines in cancer.

  2024cites this paper
• Harnessing potential role of gangliosides in immunomodulation and cancer therapeutics.

  2024cites this paper
• Neoadjuvant therapy for melanoma: past, present, and future.

  2024cites this paper
• Molecular Markers in Melanoma Progression: A Study on the Expression of miRNA Gene Subtypes in Tumoral vs. Benign Nevi

  2024cites this paper
• Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy

  2023cites this paper
• Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis

  2023cites this paper
• Immunotherapy for mucosal melanoma

  2023cites this paper
• Therapeutic Cancer Vaccines for Nonmelanoma Skin Cancer

  2023cites this paper
• Efficacy and safety of interferon-alpha 1b combined with PD-1 monoclonal antibody in patients with unresectable stage IV melanoma: a retrospective study

  2023cites this paper
• Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field

  2023cites this paper
• Increasing cure rates of solid tumors by immune checkpoint inhibitors

  2023cites this paper
• Chemotherapy in combination with anti-PD-1 agents as adjuvant therapy for high-risk oral mucosal melanoma

  2022cites this paper
• Melanoma therapeutics: a literature review

  2022cites this paper
• Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing

  2022cites this paper
• Adjuvant treatment of high-risk melanoma – cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors

  2022cites this paper
• Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609

  2022cites this paper
• Biosurfactants as Anticancer Agents: Glycolipids Affect Skin Cells in a Differential Manner Dependent on Chemical Structure

  2022cites this paper
• Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View.

  2022cites this paper
• Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency

  2022cites this paper
• Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment

  2022cites this paper
• Systemic adjuvant therapy for high-risk cutaneous melanoma

  2022cites this paper
• Educational Review: Neoadjuvant Approaches to Melanoma

  2022cites this paper
• Protein Informatics and Vaccine Development: Cancer Case Study.

  2022cites this paper
• Toripalimab (anti-PD-1) versus High-Dose Interferon-α2b as Adjuvant Therapy in Resected Mucosal Melanoma: A Phase II Randomized Trial.

  2022cites this paper
• A Double-Edged Sword Role of Cytokines in Prostate Cancer Immunotherapy

  2021cites this paper
• miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma

  2021cites this paper
• Anti-glycan antibodies: roles in human disease.

  2021cites this paper
• New partition based measures for data compatibility and information gain

  2021cites this paper
• Pediatric Melanoma-Diagnosis, Management, and Anticipated Outcomes.

  2021cites this paper
• The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy

  2021cites this paper
• Cytokines in the Treatment of Melanoma

  2021cites this paper
• Vaccine Therapies for Cancer: Then and Now

  2021cites this paper
• State of Melanoma: An Historic Overview of a Field in Transition.

  2021cites this paper
• Adjuvant Therapy of Melanoma.

  2021cites this paper
• Interferon-α1b for the treatment of metastatic melanoma: results of a retrospective study

  2021cites this paper
• A Dual Role of Type I Interferons in Antitumor Immunity

  2020cites this paper
• Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review.

  2020cites this paper
• Combination of Chemotherapy and Cytokine Therapy in Treatment of Cancers

  2020cites this paper
• p19Arf sensitizes B16 melanoma cells to interferon-β delivered via mesenchymal stem cells in vitro

  2020cites this paper
• Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity

  2020cites this paper
• Ex vivo-generated dendritic cell-based vaccines in melanoma: the role of nanoparticulate delivery systems.

  2020cites this paper
• Molecular characterization of the immune microenvironment in melanoma

  2020cites this paper
• Tratamiento adyuvante de melanoma cutáneo : indicaciones y alternativas.

  2020cites this paper
• Cutaneous melanoma and the immunotherapy revolution (Review)

  2020cites this paper
• Molecular and functional characterization of the role of the histone methyltransferase SETDB1 in malignant melanoma

  2020cites this paper
• Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany

  2020cites this paper
• Melanoma Vaccines

  2020cites this paper
• The Role of Medical Therapy for Menigniomas

  2020cites this paper
• The current state of adjuvant therapy of melanoma.

  2020cites this paper
• Melanoma Diagnosis and Treatment in the Elderly

  2020cites this paper
• Meningiomas: Comprehensive Strategies for Management

  2020cites this paper
• Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database

  2020cites this paper
• The Role of Neoadjuvant Therapy in Melanoma

  2020cites this paper
• Adjuvant Therapy for Melanoma: Past, Current, and Future Developments

  2020cites this paper
• Adjuvant Systemic Therapy for High-Risk Melanoma Patients

  2020cites this paper
• The extent of surgery for stage III melanoma: how much is appropriate?

  2019cites this paper
• An updated analysis of 4 randomized ECOG trials of high‐dose interferon in the adjuvant treatment of melanoma

  2019cites this paper
• Cancer Vaccines.

  2019cites this paper
• Current Immunotherapy Practices in Melanoma.

  2019cites this paper
• Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.

  2019cites this paper
• Melanoma

  2019cites this paper
• Sentinel Lymph Node Biopsy for Eyelid and Conjunctival Malignancies

  2019cites this paper
• A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma

  2019cites this paper
• Glycoconjugate vaccines: some observations on carrier and production methods.

  2019cites this paper
• Patterns of immunotherapy use and management of toxicities in regional and tertiary settings

  2019cites this paper
• Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment

  2019cites this paper
• Photodynamic Modulation of Type 1 Interferon Pathway on Melanoma Cells Promotes Dendritic Cell Activation

  2019cites this paper
• Novel mechanism of dendritic cell maturation by dying/death tumor cells via photodynamic modulation of type 1 interferon pathway

  2019cites this paper
• Systemic Therapies for Advanced Melanoma.

  2019cites this paper
• Neoadjuvant therapy of locally/regionally advanced melanoma

  2019cites this paper
• Cutaneous Melanoma , Version 2 . 2019

  2019cites this paper
• What's New in Pediatric Melanoma: An Update from the APSA Cancer Committee.

  2019cites this paper
• Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

  2019cites this paper
• Medical Options for the Adjuvant Treatment and Management of Pediatric Melanoma

  2019cites this paper
• Adjuvant and Neoadjuvant Treatment of Skin Cancer.

  2019cites this paper
• Immunotherapy of Melanoma: Facts and Hopes

  2019influential citation
• Aging, Cancer and Immunity

  2019cites this paper
• Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma.

  2019cites this paper
• Shared and Distinct Functions of Type I and Type III Interferons.

  2019cites this paper
• Approaches to High-Risk Resected Stage II and III Melanoma.

  2019cites this paper
• Vaccination with Tumor-Ganglioside Glycomimetics Activates a Selective Immunity that Affords Cancer Therapy.

  2019cites this paper
• Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities.

  2019cites this paper